Atyr Pharma Inc. (NASDAQ:LIFE) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.
According to Zacks, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. “
Several other analysts have also recently commented on the company. Citigroup Inc. raised their target price on Atyr Pharma from $3.00 to $4.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 16th. JPMorgan Chase & Co. reduced their price objective on Atyr Pharma from $15.00 to $10.00 and set an “overweight” rating for the company in a research report on Thursday, August 11th. Finally, BMO Capital Markets set a $8.00 price objective on Atyr Pharma and gave the company a “hold” rating in a research report on Thursday, October 6th. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $6.50.
Atyr Pharma (NASDAQ:LIFE) opened at 2.88 on Wednesday. The firm’s market capitalization is $68.31 million. Atyr Pharma has a 1-year low of $2.48 and a 1-year high of $13.26. The company has a 50-day moving average price of $3.10 and a 200 day moving average price of $3.23.
Atyr Pharma (NASDAQ:LIFE) last issued its earnings results on Wednesday, August 10th. The company reported ($0.65) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.71) by $0.06. Equities analysts anticipate that Atyr Pharma will post ($2.56) earnings per share for the current year.
Several hedge funds have recently modified their holdings of LIFE. GSA Capital Partners LLP purchased a new stake in Atyr Pharma during the second quarter worth approximately $101,000. A.R.T. Advisors LLC boosted its stake in Atyr Pharma by 88.8% in the second quarter. A.R.T. Advisors LLC now owns 39,143 shares of the company’s stock worth $108,000 after buying an additional 18,410 shares in the last quarter. Bridgeway Capital Management Inc. purchased a new stake in Atyr Pharma during the second quarter worth approximately $133,000. Jackson Park Capital LLC purchased a new stake in Atyr Pharma during the second quarter worth approximately $183,000. Finally, Emerald Acquisition Ltd. purchased a new stake in Atyr Pharma during the second quarter worth approximately $206,000. Institutional investors own 44.75% of the company’s stock.
About Atyr Pharma
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atyr Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.